(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 January 2026 (08.01.2026)

WIPO | PCT

(10) International Publication Number
WO 2026/010658 A3

(51) International Patent Classification:
A61K 51/04 (2006.01) *A61K 51/12* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2025/021148

(22) International Filing Date:
24 March 2025 (24.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,863 22 March 2024 (22.03.2024) US

(71) Applicants: **NUCLIDIUM AG** [CH/CH]; Im Erasmushaus, Baumleingasse 18, 4051 Basel (CH). **UNIVERSITY OF BASEL** [CH/CH]; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH).


(72) Inventors: **JAAFAR-THIEL, Leila**; Im Erasmushaus, Baumleingasse 18, 4051 Basel (CH). **DE ROSE, Francesco**; Im Erasmuhaus, Baumleingasse 18, 4051 Basel (CH). **FANI, Melpomeni**; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH). **MILLUL, Jacopo**; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH).

(74) Agent: **MORALES, Carl, A.** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: FIBROBLAST ACTIVATION PROTEIN-TARGETING RADIOPHARMACEUTICALS AND USES THEREOF



A B C

FIG. 1

(57) Abstract: The present disclosure relates to pharmaceutical compositions comprising a [^{61}Cu]Cu-labeled fibroblast activation protein (FAP) inhibitor-NODAGA conjugate. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a FAP-expressing cancer or tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

[Continued on next page]

WO 2026/010658 A3

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
19 March 2026 (19.03.2026)